Table 1.
Description of study patients
| Subjects N (%) | Systolic/Diastolic BP mmHg (STD) | Charlson comorbidity index (STD) | Prior healthcare expenditure $ (STD) | |
|---|---|---|---|---|
| Age | p = 0.0003/p = 0.0007 | p = 0.0043 | p = 0.0916 | |
| <40 | 33 (14.80) | 153.5 (13.3)/95.3 (11.3) | 0.18 (0.58) | 1,173 (1,163) |
| 40–60 | 123 (55.16) | 155.8 (16.8)/95.7 (9.6) | 0.21 (0.87) | 2,069 (3,214) |
| ≥60 | 67 (30.04) | 165.2 (18.0)/88.6 (16.5) | 0.70 (1.33) | 2,664 (3,728) |
| Gender | p = 0.2207/p = 0.0974 | p = 0.7689 | p = 0.3693 | |
| Female | 115 (51.57) | 159.7 (17.8)/92.1 (12.0) | 0.33 (1.03) | 2,304 (2,919) |
| Male | 108 (48.43) | 156.8 (16.5)/95.0 (13.2) | 0.37 (1.02) | 1,915 (3,529) |
| Hypertension Staging† | p = 0.0001/p = 0.0001 | p = 0.1638 | p = 0.6471 | |
| Stage 1 | 88 (39.46) | 145.0 (7.7)/87.0 (7.8) | 0.47(1.09) | 2,238 (2,809) |
| Stage 2 | 135 (60.35) | 166.9 (16.3)/97.8 (13.5) | 0.28(0.97) | 2,035(3,480) |
| Diabetes/renal disease | p = 0.9111/p = 0.0075 | p = 0.0001 | p = 0.1772 | |
| No | 176 (78.92) | 158.4 (16.9)/94.7 (12.7) | 0.14 (0.72) | 1,964 (3,044) |
| Yes | 47 (21.08) | 158.0 (18.7)/89.1 (11.7) | 1.14 (1.50) | 2,680 (3,821) |
| Drug therapy option | p = 0.0117/p = 0.9668 | p = 0.8090 | p = 0.3135 | |
| One | 177 (79.37) | 156.8 (17.1)/93.5 (12.5) | 0.36 (1.06) | 2,004 (2,970) |
| Two or More | 46 (20.63) | 164.0 (16.9)/93.6 (13.3) | 0.32 (0.84) | 2,544 (4,080) |
| Total | 223 (100.00) | 158.3 (17.2)/93.5 (12.7) | 0.35 (1.02) | 2,115 (3,227) |
†
Stage is 1 if baseline systolic BP less than 160 mmHg and/or diastolic BP less than 100 mmHg. Otherwise, Stage = 2. P‐values are from one‐way ANOVA (analysis of variance).